R&G PharmaStudies Co. Ltd. A - Asset Resilience Ratio
R&G PharmaStudies Co. Ltd. A (301333) has an Asset Resilience Ratio of 23.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 301333 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how R&G PharmaStudies Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see R&G PharmaStudies Co. Ltd. A asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down R&G PharmaStudies Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read R&G PharmaStudies Co. Ltd. A (301333) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥574.90 Million | 23.94% |
| Total Liquid Assets | CN¥574.90 Million | 23.94% |
Asset Resilience Insights
- Good Liquidity Position: R&G PharmaStudies Co. Ltd. A maintains a healthy 23.94% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
R&G PharmaStudies Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare R&G PharmaStudies Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for R&G PharmaStudies Co. Ltd. A (2023–2025)
The table below shows the annual Asset Resilience Ratio data for R&G PharmaStudies Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.84% | CN¥620.12 Million ≈ $90.74 Million |
CN¥2.40 Billion ≈ $351.14 Million |
-4.45pp |
| 2024-12-31 | 30.29% | CN¥707.61 Million ≈ $103.55 Million |
CN¥2.34 Billion ≈ $341.86 Million |
-4.06pp |
| 2023-12-31 | 34.35% | CN¥712.39 Million ≈ $104.24 Million |
CN¥2.07 Billion ≈ $303.46 Million |
-- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more